244 related articles for article (PubMed ID: 19046911)
1. Pharmacodynamic target attainment potential of azithromycin, clarithromycin, and telithromycin in serum and epithelial lining fluid of community-acquired pneumonia patients with penicillin-susceptible, intermediate, and resistant Streptococcus pneumoniae.
Noreddin AM; El-Khatib WF; Aolie J; Salem AH; Zhanel GG
Int J Infect Dis; 2009 Jul; 13(4):483-7. PubMed ID: 19046911
[TBL] [Abstract][Full Text] [Related]
2. Comparative pharmacodynamics of garenoxacin, gemifloxacin, and moxifloxacin in community-acquired pneumonia caused by Streptococcus pneumoniae: a Monte Carlo simulation analysis.
Noreddin AM; Reese AA; Ostroski M; Hoban DJ; Zhanel GG
Clin Ther; 2007 Dec; 29(12):2685-9. PubMed ID: 18201584
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrations.
Zhanel GG; DeCorby M; Noreddin A; Mendoza C; Cumming A; Nichol K; Wierzbowski A; Hoban DJ
J Antimicrob Chemother; 2003 Jul; 52(1):83-8. PubMed ID: 12775677
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity and pharmacodynamics of azithromycin and clarithromycin against Streptococcus pneumoniae based on serum and intrapulmonary pharmacokinetics.
Kays MB; Denys GA
Clin Ther; 2001 Mar; 23(3):413-24. PubMed ID: 11318076
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamic activity of telithromycin against macrolide-susceptible and macrolide-resistant Streptococcus pneumoniae simulating clinically achievable free serum and epithelial lining fluid concentrations.
Zhanel GG; Johanson C; Hisanaga T; Mendoza C; Laing N; Noreddin A; Wierzbowski A; Hoban DJ
J Antimicrob Chemother; 2004 Dec; 54(6):1072-7. PubMed ID: 15531596
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic modelling of serum and bronchial concentrations for clarithromycin and telithromycin, and site-specific pharmacodynamic simulation for their dosages.
Ikawa K; Kikuchi E; Kikuchi J; Nishimura M; Derendorf H; Morikawa N
J Clin Pharm Ther; 2014 Aug; 39(4):411-7. PubMed ID: 24661290
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic activity of telithromycin at simulated clinically achievable free-drug concentrations in serum and epithelial lining fluid against efflux (mefE)-producing macrolide-resistant Streptococcus pneumoniae for which telithromycin MICs vary.
Zhanel GG; Johanson C; Laing N; Hisanaga T; Wierzbowski A; Hoban DJ
Antimicrob Agents Chemother; 2005 May; 49(5):1943-8. PubMed ID: 15855517
[TBL] [Abstract][Full Text] [Related]
8. Comparative activity of telithromycin against typical community-acquired respiratory pathogens.
Buxbaum A; Forsthuber S; Graninger W; Georgopoulos A
J Antimicrob Chemother; 2003 Sep; 52(3):371-4. PubMed ID: 12888585
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP).
Noreddin AM; Marras TK; Sanders K; Chan CK; Hoban DJ; Zhanel GG
Int J Antimicrob Agents; 2004 Nov; 24(5):479-84. PubMed ID: 15519481
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic options for pneumococcal pneumonia in Turkey.
Oncu S; Erdem H; Pahsa A
Clin Ther; 2005 Jun; 27(6):674-83. PubMed ID: 16117975
[TBL] [Abstract][Full Text] [Related]
11. Comparative pharmacodynamics of telithromycin and clarithromycin with Streptococcus pneumoniae and Staphylococcus aureus in an in vitro dynamic model: focus on clinically achievable antibiotic concentrations.
Alferova IV; Vostrov SN; Portnoy YA; Lubenko IY; Zinner SH; Firsov AA
Int J Antimicrob Agents; 2005 Sep; 26(3):197-204. PubMed ID: 16122914
[TBL] [Abstract][Full Text] [Related]
12. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia.
Tellier G; Niederman MS; Nusrat R; Patel M; Lavin B
J Antimicrob Chemother; 2004 Aug; 54(2):515-23. PubMed ID: 15269191
[TBL] [Abstract][Full Text] [Related]
13. Azithromycin iv pharmacodynamic parameters predicting Streptococcus pneumoniae killing in epithelial lining fluid versus serum: an in vitro pharmacodynamic simulation.
Sevillano D; Alou L; Aguilar L; Echevarría O; Giménez MJ; Prieto J
J Antimicrob Chemother; 2006 Jun; 57(6):1128-33. PubMed ID: 16617063
[TBL] [Abstract][Full Text] [Related]
14. Selection of resistance of telithromycin against Haemophilus influenzae, Moraxella catarrhalis and streptococci in comparison with macrolides.
Drago L; De Vecchi E; Nicola L; Colombo A; Gismondo MR
J Antimicrob Chemother; 2004 Aug; 54(2):542-5. PubMed ID: 15215227
[TBL] [Abstract][Full Text] [Related]
15. A pharmacodynamic approach to antimicrobial activity in serum and epithelial lining fluid against in vivo-selected Streptococcus pneumoniae mutants and association with clinical failure in pneumonia.
Alou L; Giménez MJ; Sevillano D; Aguilar L; Cafini F; Echeverría O; Pérez-Trallero E; Prieto J
J Antimicrob Chemother; 2006 Aug; 58(2):349-58. PubMed ID: 16782744
[TBL] [Abstract][Full Text] [Related]
16. Disposition of oral telithromycin in foals and in vitro activity of the drug against macrolide-susceptible and macrolide-resistant Rhodococcus equi isolates.
Javsicas LH; Giguère S; Womble AY
J Vet Pharmacol Ther; 2010 Aug; 33(4):383-8. PubMed ID: 20646201
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic profile of telithromycin against macrolide- and fluoroquinolone-resistant Streptococcus pneumoniae in a neutropenic mouse thigh model.
Tessier PR; Mattoes HM; Dandekar PK; Nightingale CH; Nicolau DP
Antimicrob Agents Chemother; 2005 Jan; 49(1):188-94. PubMed ID: 15616295
[TBL] [Abstract][Full Text] [Related]
18. Susceptibilities of Streptococcus pyogenes and Streptococcus pneumoniae to macrolides and telithromycin: data from an Italian multicenter study.
Mazzariol A; Koncan R; Bahar G; Cornaglia G
J Chemother; 2007 Oct; 19(5):500-7. PubMed ID: 18073148
[TBL] [Abstract][Full Text] [Related]
19. Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae.
Noreddin AM; Hoban DJ; Zhanel GG
Int J Antimicrob Agents; 2005 Aug; 26(2):120-5. PubMed ID: 16046101
[TBL] [Abstract][Full Text] [Related]
20. Development of macrolide-resistance and comparative activity of telithromycin in streptococci in Austria, 1996-2002.
Buxbaum A; Forsthuber S; Sauermann R; Gattringer R; Graninger W; Georgopoulos A;
Int J Antimicrob Agents; 2004 Oct; 24(4):397-400. PubMed ID: 15380268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
